| [1] |
He YB, Sun JS, Wang ZP, et al.Risk factors of early liver dysfunction after liver transplantation using grafts from donation after citizen death donors[J].Transpl Immunol, 2022, 71:101525.
|
| [2] |
Spitzer AL, Lao OB, Dick AA, et al.The biopsied donor liver:incorporating macrosteatosis into high-risk donor assessment[J].Liver Transpl, 2010, 16(7):874-884.
|
| [3] |
Wang K, Lu D, Liu Y, et al.Severity of early allograft dysfunction following donation after circulatory death liver transplantation: a multicentre study[J].Hepatobiliary Surg Nutr, 2021, 10(1):9-19.
|
| [4] |
Chu MJ, Hickey AJ, Phillips AR, et al.The impact of hepatic steatosis on hepatic ischemia-reperfusion injury in experimental studies: a systematic review[J].Biomed Res Int, 2013, 2013:192029.
|
| [5] |
de Graaf EL, Kench J, Dilworth P, et al.Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index[J].J Gastroenterol Hepatol, 2012,27(3):540-546.
|
| [6] |
Loomba R, Kayali Z, Noureddin M, et al.GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease[J].Gastroenterology, 2018, 155(5):1463-1473, e6.
|
| [7] |
Calle RA, Amin NB, Carvajal-Gonzalez S, et al.ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials[J].Nat Med, 2021, 27(10):1836-1848.
|
| [8] |
Syed-Abdul MM, Parks EJ, Gaballah AH, et al.Fatty acid synthase inhibitor TVB-2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities[J].Hepatology, 2020, 72(1):103-118.
|
| [9] |
Ratziu V, de Guevara L, Safadi R, et al.Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebocontrolled phase 2b trial[J].Nat Med, 2021, 27(10):1825-1835.
|
| [10] |
Loomba R, Morgan E, Watts L, et al.Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebocontrolled phase 2 trial[J].Lancet Gastroenterol Hepatol, 2020,5(9):829-838.
|
| [11] |
Aoudjehane L, Gautheron J, Le Goff W, et al.Novel defatting strategies reduce lipid accumulation in primary human culture models of liver steatosis[J].Dis Model Mech, 2020, 13(4): dmm042663.
|
| [12] |
Zhou W, Ye S.Rapamycin improves insulin resistance and hepatic steatosis in type 2 diabetes rats through activation of autophagy[J].Cell Biol Int, 2018, 42(10):1282-1291.
|
| [13] |
Chen H, Shen F, Sherban A, et al.DEP domain-containing mTORinteracting protein suppresses lipogenesis and ameliorates hepatic steatosis and acute-on-chronic liver injury in alcoholic liver disease[J].Hepatology, 2018, 68(2):496-514.
|
| [14] |
Harrison SA, Rinella ME, Abdelmalek MF, et al.NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised,double-blind, placebo-controlled, phase 2 trial[J].Lancet, 2018,391(10126):1174-1185.
|
| [15] |
Sanyal A, Charles ED, Neuschwander-Tetri BA, et al.Pegbelfermin(BMS-986036), a PEGylated fibroblast growth factor 21 analogue,in patients with non-alcoholic steatohepatitis: a randomised,double-blind, placebo-controlled, phase 2a trial[J].Lancet, 2019,392(10165):2705-2717.
|
| [16] |
Loomba R, Lawitz EJ, Frias JP, et al.Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study[J].Lancet Gastroenterol Hepatol,2023, 8(2):120-132.
|
| [17] |
Kleiboeker B, Lodhi IJ.Peroxisomal regulation of energy homeostasis:effect on obesity and related metabolic disorders[J].Mol Metab, 2022,65:101577.
|
| [18] |
Wang H, Bell M, Sreenivasan U, et al.Unique regulation of adipose triglyceride lipase (ATGL) by perilipin 5, a lipid droplet-associated protein[J].J Biol Chem, 2011, 286(18):15707-15715.
|
| [19] |
Pégorier JP, Garcia-Garcia MV, Prip-Buus C, et al.Induction of ketogenesis and fatty acid oxidation by glucagon and cyclic AMP in cultured hepatocytes from rabbit fetuses.Evidence for a decreased sensitivity of carnitine palmitoyltransferase I to malonyl-CoA inhibition after glucagon or cyclic AMP treatment[J].Biochem J,1989, 264(1):93-100.
|
| [20] |
Nativ NI, Yarmush G, Chen A, et al.Rat hepatocyte culture model of macrosteatosis: effect of macrosteatosis induction and reversal on viability and liver-specific function[J].J Hepatol, 2013, 59(6):1307-1314.
|
| [21] |
Nagrath D, Xu H, Tanimura Y, et al.Metabolic preconditioning of donor organs: defatting fatty livers by normothermic perfusion ex vivo[J].Metab Eng, 2009, 11(4/5):274-283.
|
| [22] |
Harrison SA, Bashir MR, Guy CD, et al.Resmetirom (MGL-3196)for the treatment of non-alcoholic steatohepatitis: a multicentre,randomised, double-blind, placebo-controlled, phase 2 trial[J].Lancet,2019, 394(10213):2012-2024.
|
| [23] |
Li JY, Cao HY, Sun L, et al.Therapeutic mechanism of Yīn-Chén-Hāo decoction in hepatic diseases[J].World J Gastroenterol, 2017,23(7):1125-1138.
|
| [24] |
Francque SM, Bedossa P, Ratziu V, et al.A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH[J].N Engl J Med,2021, 385(17):1547-1558.
|
| [25] |
Ratziu V, Harrison SA, Francque S, et al.Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J].Gastroenterology, 2016, 150(5):1147-1159, e5.
|
| [26] |
Gawrieh S, Noureddin M, Loo N, et al.Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled doubleblind phase 2 trial[J].Hepatology, 2021, 74(4):1809-1824.
|
| [27] |
Kazierad DJ, Chidsey K, Somayaji VR, et al.Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial[J].Med, 2021,2(7):800-813, e3.
|
| [28] |
Harrison SA, Alkhouri N, Davison BA, et al.Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, doubleblind, placebo-controlled phase IIb study[J].J Hepatol, 2020, 72(4):613-626.
|
| [29] |
Xu H, Du X, Liu G, et al.The pseudokinase MLKL regulates hepatic insulin sensitivity independently of inflammation[J].Mol Metab, 2019,23:14-23.
|
| [30] |
Newsome PN, Buchholtz K, Cusi K, et al.A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J].N Engl J Med, 2021, 384(12):1113-1124.
|
| [31] |
Cusi K, Bril F, Barb D, et al.Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes[J].Diabetes Obes Metab, 2019, 21(4):812-821.
|
| [32] |
Younossi ZM, Ratziu V, Loomba R, et al.Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J].Lancet,2019, 394(10215):2184-2196.
|
| [33] |
Harrison SA, Bashir MR, Lee KJ, et al.A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis[J].J Hepatol, 2021, 75(1):25-33.
|
| [34] |
Patel K, Harrison SA, Elkhashab M, et al.Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial[J].Hepatology, 2020, 72(1):58-71.
|
| [35] |
Girisa S, Henamayee S, Parama D, et al.Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer[J].Mol Biomed, 2021, 2(1):21.
|
| [36] |
Jia JJ, Li JH, Yu H, et al.Machine perfusion for liver transplantation:a concise review of clinical trials[J].Hepatobiliary Pancreat Dis Int,2018, 17(5):387-391.
|
| [37] |
Bessems M, Doorschodt BM, Kolkert JL, et al.Preservation of steatotic livers: a comparison between cold storage and machine perfusion preservation[J].Liver Transpl, 2007, 13(4):497-504.
|
| [38] |
Kron P, Schlegel A, Mancina L, et al.Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans[J].J Hepatol, 2017: S0168-S8278(17)32268-7.
|
| [39] |
Guarrera JV, Henry SD, Samstein B, et al.Hypothermic machine preservation in human liver transplantation: the first clinical series[J].Am J Transplant, 2010, 10(2):372-381.
|
| [40] |
Jamieson RW, Zilvetti M, Roy D, et al.Hepatic steatosis and normothermic perfusion-preliminary experiments in a porcine model[J].Transplantation, 2011, 92(3):289-295.
|
| [41] |
Liu Q, Nassar A, Buccini L, et al.Lipid metabolism and functional assessment of discarded human livers with steatosis undergoing 24 hours of normothermic machine perfusion[J].Liver Transpl, 2018,24(2):233-245.
|
| [42] |
Raigani S, Carroll C, Griffith S, et al.Improvement of steatotic rat liver function with a defatting cocktail during ex situ normothermic machine perfusion is not directly related to liver fat content[J].PLoS One, 2020, 15(5): e0232886.
|
| [43] |
Boteon YL, Attard J, Boteon APCS, et al.Manipulation of lipid metabolism during normothermic machine perfusion: effect of defatting therapies on donor liver functional recovery[J].Liver Transpl, 2019, 25(7):1007-1022.
|
| [44] |
Liu Q, Berendsen T, Izamis ML, et al.Perfusion defatting at subnormothermic temperatures in steatotic rat livers[J].Transplant Proc, 2013, 45(9):3209-3213.
|
| [45] |
Taba TVS, Kailar R, Rahman K, et al.Glial cell line-derived neurotrophic factor-induced mice liver defatting: a novel strategy to enable transplantation of steatotic livers[J].Liver Transpl, 2016,22(4):459-467.
|
| [46] |
Banan B, Watson R, Xu M, et al.Development of a normothermic extracorporeal liver perfusion system toward improving viability and function of human extended criteria donor livers[J].Liver Transpl,2016, 22(7):979-993.
|
| [47] |
Sousa Da Silva RX, Bautista Borrego L, Lenggenhager D, et al.Defatting of human livers during long-term ex situ normothermic perfusion: novel strategy to rescue discarded organs for transplantation[J].Ann Surg, 2023, 278(5):669-675.
|
| [48] |
Berthiaume F, Barbe L, Mokuno Y, et al.Steatosis reversibly increases hepatocyte sensitivity to hypoxia-reoxygenation injury[J].J Surg Res,2009, 152(1):54-60.
|